Gerald Pierone, MD
Internal Medicine · Vero Beach, FLNPI 1356387435
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,600 of the $21,767 with a category attached, or 62.5%. Viiv Healthcare Company accounts for 68.8% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $13,529 and has fallen 91.3% since, to $1,174 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $75.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$15K
- Amgen$857
- Novo Nordisk$768
- AbbVie$636
- Novartis$443
- Revance Therapeutics, Inc.$396
- plus $4K from 34 others
Across 200 payments — averaging $5727.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$668K
- Gilead$201K
- GSK$160K
- AbbVie$57K
- Amgen$32K
- Merck$17K
- plus $11K from 2 others
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$13,60062%
- Travel & lodging$7734%
- Food & beverage$7,29834%
- Other$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,767 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 109 | $359,147 |
| JulucaDolutegravir/Rilpivirine | 103 | $352,121 |
| TivicayDolutegravir Sodium | 118 | $306,978 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 68 | $267,660 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 57 | $223,171 |
| IsentressRaltegravir Potassium | 112 | $218,395 |
| SerostimSomatropin | 12 | $168,527 |
| DescovyEmtricitabine/Tenofov Alafenam | 73 | $151,359 |
| Enbrel SureclickEtanercept | 15 | $130,542 |
| OzempicSemaglutide | 102 | $115,869 |
| EliquisApixaban | 95 | $109,706 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 25 | $89,124 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $83,218 |
| Etravirine | 78 | $68,526 |
| PrezcobixDarunavir/Cobicistat | 24 | $61,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Juluca, Tivicay, Cabenuva | $14,986 | $1,101,464343 claims |
| GileadBiktarvy, Genvoya, Descovy, Vemlidy, Tybost | $269 | $661,288223 claims |
| MerckIsentress | $98 | $218,395112 claims |
| Novo NordiskOzempic | $768 | $115,869102 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $183 | $94,65151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $333 | $42,52643 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $288 | $35,70185 claims |
| Boehringer IngelheimJardiance | $193 | $30,26738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Vero Beach
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.